Literature DB >> 9239426

Cardiac disease in chronic uremia: pathophysiology.

K Amann1, E Ritz.   

Abstract

In chronic uremia, apart from frequent coronary lesions, further abnormalities of the heart recently reported include (1) left ventricular hypertrophy, not completely explained by hypertension, (2) interstitial myocardial fibrosis, for which parathyroid hormone is a permissive factor, (3) reduced myocardial perfusion reserve, secondary to functional and structural changes of intramyocardial arteries and to reduced capillary density, (4) abnormalities of myocardial metabolism, which act in concert with restriction of blood flow by microvascular abnormalities to reduce ischemic tolerance. Such metabolic abnormalities include diminished responsiveness to beta-adrenergic stimulation, abnormal control of intracellular calcium concentration, impaired maintenance of energy-rich nucleotide concentrations under conditions of ischemia, impaired insulin-mediated glucose uptake, and abnormalities of myocardial oxidative metabolism.

Entities:  

Mesh:

Year:  1997        PMID: 9239426     DOI: 10.1016/s1073-4449(97)70030-x

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  14 in total

Review 1.  Sudden cardiac death in end stage renal disease: unlocking the mystery.

Authors:  D Zachariah; P R Kalra; Paul R Roberts
Journal:  J Nephrol       Date:  2014-11-13       Impact factor: 3.902

2.  Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting.

Authors:  C Le Feuvre; G Dambrin; G Helft; F Beygui; M Touam; J P Grünfeld; A Vacheron; J P Metzger
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

3.  Assessment of residual alveolar bone volume in hemodialysis patients using CBCT.

Authors:  Dan Zhao; Xiaolei Chen; Li Yue; Weiqing Liu; Anchun Mo; Haiyang Yu; Quan Yuan
Journal:  Clin Oral Investig       Date:  2015-01-25       Impact factor: 3.573

4.  Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis.

Authors:  N Al-Hilali; N Hussain; A I Ataia; M Al-Azmi; B Al-Helal; K V Johny
Journal:  Indian J Nephrol       Date:  2009-10

5.  Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?

Authors:  Charles A Herzog; Jeremy W Strief; Allan J Collins; David T Gilbertson
Journal:  Nephrol Dial Transplant       Date:  2008-02-25       Impact factor: 5.992

Review 6.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

7.  Candesartan cilexetil in haemodialysis patients.

Authors:  Pia Ottosson; Per-Ola Attman; Ann-Charlotte Agren; Ola Samuelsson
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

8.  Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION).

Authors:  Claudiu Stoicescu; Vlad Vintila; Cristian Udroiu; Nicolae Florescu; Aws Dawood; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2013-06

9.  The association between parathyroid hormone and mortality in dialysis patients is modified by wasting.

Authors:  Christiane Drechsler; Vera Krane; Diana C Grootendorst; Eberhard Ritz; Karl Winkler; Winfried März; Friedo Dekker; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2009-05-27       Impact factor: 5.992

10.  Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.

Authors:  Christiane Drechsler; Eberhard Ritz; Andreas Tomaschitz; Stefan Pilz; Stephan Schönfeld; Katja Blouin; Martin Bidlingmaier; Fabian Hammer; Vera Krane; Winfried März; Bruno Allolio; Martin Fassnacht; Christoph Wanner
Journal:  Eur Heart J       Date:  2012-12-04       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.